Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002754 | 0.87 | KDM4E (0.46) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16432412 | 0.83 | GRIN2D (0.51) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24392618 | 0.83 | KDM4E (0.43) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1805702 | 0.81 | QPCT (0.39) | SRCKDM4EALDH1A1HPGDGRIN2D | |
| Hydrochloric Acid SCHEMBL28068007 | 0.81 | GRIN2D (0.50) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16636918 | 0.79 | GRIN2D (0.51) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30822504 | 0.79 | GRIN2D (0.51) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3901620 | 0.79 | SRC (0.38) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1806456 | 0.79 | PDE3B (0.47) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4430431 | 0.77 | TNFSF11 (0.50) | SRCKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| EP-3323819-B1 | COMBINATIONS OF RIP2 KINASE INHIBITOR PRODRUG 2-((4-(BENZO[D]THIAZOL-5-YLAMINO)-6-(TERT. -BUTYLSULFONYL)QUINAZOLIN-7-YL)OXY)ETHYL DIHYDROGEN PHOSPHATE WITH OTHER THERAPEUTIC AGENTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| EP-3323819-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| EP-2895174-B1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-01-10 | — | — | EP | disclosed |
| US-20170258794-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9695161-B2 | Prodrugs of amino quinazoline kinase inhibitor | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9586953-B2 | Prodrugs of amino quinazoline kinase inhibitor | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160207913-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE LLC | 2016-07-21 | — | — | US | disclosed |
| EP-2895174-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-20150045323-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-12 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2744501-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014043446-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | SRC 248/4885KDM4E 770/4885ALDH1A1 3819/4885 |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | SRC 248/4885KDM4E 770/4885ALDH1A1 3819/4885 |
| US-20170258794-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | DCK, ABL1, MAP3K19 | SRC 331/4885KDM4E 782/4885ALDH1A1 2635/4885 |
| US-20150045323-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | DCK, ABL1, MAP3K19 | SRC 331/4885KDM4E 782/4885ALDH1A1 2635/4885 |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | SRC 248/4885KDM4E 770/4885ALDH1A1 3819/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | SRC 248/4885KDM4E 770/4885ALDH1A1 3819/4885 |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | SRC 281/4885KDM4E 785/4885ALDH1A1 3497/4885 |
| US-20160207913-A1 | PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR | DCK, ABL1, MAP3K19 | SRC 331/4885KDM4E 782/4885ALDH1A1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.